Clinical trials: Lifestyle-Related Condition
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Conduct Disorder
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior.
- Trial name
- NCT00154362
- Testing
- Oxcarbazepine
- Volunteers
- 50 people
- Sponsor
- Novartis
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00610441
- Testing
- MK-8777
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Disorder With Hyperactivity
Assessment of ARVO Web-based Software for Evaluating Attention-Deficit/Hyperactive Disorder (ADHD) Symptoms in Children
Clinical investigation is aimed to assess the performance and safety of web-based ARVO 2.0, for evaluating possible Attention-Deficit/Hyperactive Disorder (ADHD) symptoms in children.
- Trial name
- NCT05846815
- Testing
- ARVO 2.0 WEB, Conners Continuous Performance Test 3rd Edition™ (CPT 3)
- Where
- Finland
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Peili Vision Ltd.
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Opioid-use Disorder, Opioid-related Disorders
An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine…
- Trial name
- RECOVER® (NCT03604861)
- Testing
- Not applicable - no defined intervention
- Where
- 35 sites in United States
- Volunteers
- 534 people
- Sponsor
- Indivior Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
- Trial name
- ADHD (NCT06215144)
- Testing
- NRCT-101SR
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Neurocentria, Inc.
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT02734693
- Testing
- dasotraline 4mg
- Where
- 5 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD
Efficacy of Neuro+ Attention Training
This study evaluates the efficacy of the Neuro+ Attention Training System (Neuro+) in improving attention skills in children. Half of participants will receive the Neuro+ intervention for 10 weeks, while the other half will…
- Trial name
- NCT02642055
- Testing
- Neuro+ Attention Training, Treatment as Usual
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Neuro+
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.
- Trial name
- NCT00485550
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eli Lilly and Company
REM Sleep Behavior Disorder
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder
This study is to investigate the safety and efficacy of PXS-4728A as an intervention therapy in participants with iRBD. This study will be conducted in participants aged 50 to 80 years of age and will investigate a single dose…
- Trial name
- NCT05904717
- Testing
- PXS-4728 (A)
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Syntara
Attention Deficit Hyperactivity Disorder
Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa
Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty…
- Trial name
- ADD201 (NCT00983814)
- Testing
- Droxidopa+Carbidopa
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Chelsea Therapeutics
Attention Deficit Hyperactivity Disorder
A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety of methylphenidate HCL extended-release tablets at five dose levels in adults with Attention Deficit Hyperactivity Disorder (ADHD)
- Trial name
- NCT00326300
- Testing
- methylphenidate hydrochloride extended-release tablets
- Volunteers
- 560 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
ADHD
Observational Study to Assess the Frequency of Lidocaine Ineffectiveness in Hard-to-treat ADHD
This work will assess the prevalence in hard-to-treat ADHD of the ineffectiveness of the anesthetic Lidocaine.
- Trial name
- NCT04167189
- Testing
- Lidocaine gel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- PhenoSolve, LLC
Attention Deficit Disorder With Hyperactivity
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00556959
- Testing
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release
- Where
- 13 sites in United States
- Volunteers
- 236 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.
The purpose of this study is to characterize the safety and tolerability of TAK-137 when administered as multiple oral doses in adults with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT02163915
- Testing
- TAK-137
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Takeda
Attention Deficit Disorder With Hyperactivity
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
The primary objective of this study is to evaluate the long-term safety and tolerability of methylphenidate hydrochloride extended-release capsules (Aptensio XR®) in children aged 4-5 years who have been diagnosed with…
- Trial name
- EF004 (NCT02677519)
- Testing
- Aptensio XR
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Adult ADHD
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
- Trial name
- NCT01012375
- Testing
- AZD1446
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- AstraZeneca